GlassScriptPhysician profile
Marla Dempsey
NPI 1427432335
$10,576.90
in general payments reported to CMS, 2019-2025
39 companies · $1,270 in 2025
The $1,270 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $708 · 2020: $939 · 2021: $1,943 · 2022: $1,475 · 2023: $2,516 · 2024: $1,727 · 2025: $1,270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,513.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,512.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,656.69 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,613.41 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Glaxosmithkline, LLC. | $1,234.46 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,047.83 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $863.57 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $663.61 | 2019-2025 | Xifaxan |
| Lilly USA, LLC | $397.85 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $368.47 | 2019-2025 | Otezla, Repatha, Repatha |
| Teva Pharmaceuticals USA, INC. | $262.21 | 2019-2022 | |
| Allergan, INC. | $239.87 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $200.18 | 2023-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $179.45 | 2019-2025 | Gardasil 9, Vaxneuvance, Verquvo |
| Biohaven Pharmaceuticals, INC. | $145.97 | 2021 | |
| Dexcom, INC. | $140.39 | 2022-2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.74 | 2019-2025 | Jardiance |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $126.71 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Daiichi Sankyo INC. | $123.72 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $117.55 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $110.29 | 2023-2024 | |
| Exact Sciences Corporation | $89.02 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amarin Pharma, INC. | $88.38 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $77.32 | 2019-2024 | Eliquis |
| Astellas Pharma US INC | $76.10 | 2023-2025 | Veozah |
| Radius Health, INC. | $73.19 | 2023-2025 | Tymlos |
| Abbott Laboratories | $67.52 | 2022-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $67.14 | 2023 | Gemtesa |
| Biocryst US Sales Co., LLC | $61.63 | 2023 | Orladeyo |
| Axsome Therapeutics, INC. | $61.23 | 2025 | Symbravo, Auvelity |
| Lundbeck LLC | $58.34 | 2023-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $34.58 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $34.54 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $31.34 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $30.22 | 2025 | Dupixent |
| Tactile Systems Technology INC | $20.47 | 2025 | Nimbl, Flexitouch Plus |
| Paratek Pharmaceuticals, INC. | $18.85 | 2021 | |
| Almatica Pharma LLC | $18.45 | 2022 | |
| Smith+Nephew, INC. | $17.57 | 2023 | Collagenase Santyl |
| Optinose US, INC. | $17.08 | 2023 | |
| Kaleo, INC. | $11.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marla Dempsey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.